Tripodi, A <br/><br/>
The recommended dose of idarucizumab may not always be sufficient for sustained reversal of dabigatran: comment.  [electronic resource] 

 -  Journal of thrombosis and haemostasis : JTH  09 2017 
 - 1882-1883 p.  digital 
<br/><br/> Publication Type: Letter; Comment 
<br/><br/><label>ISSN: </label>1538-7836 
<br/><br/><label>Standard No.: </label>10.1111/jth.13750  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Monoclonal, Humanized<br/>Antithrombins<br/>Dabigatran